Citigroup Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $125
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and set a price target of $125.
December 13, 2023 | 9:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has initiated coverage on Axsome Therapeutics with a Buy rating and a price target of $125, which may positively influence investor sentiment and the stock's price.
Analyst coverage, especially from a major bank like Citigroup, can significantly impact a stock's performance. A Buy rating combined with a high price target suggests strong confidence in Axsome's potential, likely leading to increased investor interest and a positive short term price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100